FT596 is an iPSC-derived NK-cell therapy engineered with a CD19-targeted CAR and the same IL-15 receptor–fusion “armoring.” In a phase 1 study for relapsed/refractory B-cell lymphomas (NCT04245722), patients received lymphodepletion followed by FT596, with or without rituximab. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.